Sarcomas | Specialty

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017

Multidisciplinary Team in Soft Tissue Sarcoma

November 14th 2017

How Sarcoma Experts Work With Community Oncologists

November 14th 2017

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

Pazopanib Regimen Active, But Misses Mark in Leiomyosarcoma

September 12th 2017

Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.

Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma

August 7th 2017

Neeta Somaiah, MD, discusses the efficacy of CMB305 in patients with synovial sarcoma or myxoid/round cell liposarcoma.

Dr. Somaiah on Next Steps for CMB305 in Soft Tissue Sarcoma

August 3rd 2017

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps following the phase I findings of the CMB305 trial in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.

10-Year Trabectedin Real-World Data Demonstrate Efficacy in Sarcoma

July 26th 2017

Long-term follow-up showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high grade soft tissue sarcomas.

Cediranib Reduces Tumor Burden in Sarcoma

July 21st 2017

Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

July 19th 2017

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

Dr. Somaiah on NY-ESO-1 Expression in Soft Tissue Sarcoma

July 7th 2017

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the expression of NY-ESO-1 in patients with soft tissue sarcoma.

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

June 23rd 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma

June 23rd 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

Aldoxorubicin Improves PFS in Advanced Soft Tissue Sarcoma

June 23rd 2017

Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.

Dr. Wilky on Determining Treatments for Sarcoma

June 23rd 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses how to determine which treatment a patient with sarcoma should receive.

FDA Grants Orphan Drug Status to Tazemetostat for Soft Tissue Sarcoma

June 22nd 2017

Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.